Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Sales and Divestitures (2019 - 2025)

Cyclerion Therapeutics has reported Gains from Sales and Divestitures over the past 7 years, most recently at $45072.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 20.56% year-over-year to $45072.0; the TTM value through Sep 2025 reached $45072.0, down 20.56%, while the annual FY2024 figure was $71763.0, 30.48% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $45072.0 at Cyclerion Therapeutics, up from $30048.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $143774.0 in Q4 2021 and troughed at $3375.0 in Q2 2023.
  • A 5-year average of $49890.1 and a median of $45072.0 in 2025 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 91.49% in 2023 and later soared 1136.0% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $143774.0 in 2021, then plummeted by 62.44% to $53999.0 in 2022, then rose by 1.85% to $55000.0 in 2023, then surged by 30.48% to $71763.0 in 2024, then tumbled by 37.19% to $45072.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CYCN at $45072.0 in Q3 2025, $30048.0 in Q2 2025, and $15024.0 in Q1 2025.